Navigation Links
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
Date:11/13/2009

STOCKHOLM, November 13 /PRNewswire/ -- Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA. The clinical trial is being conducted in Sweden on advanced-stage cancer patients with documented progressive solid tumors and no remaining treatment options. The first part of the trial has been successfully completed and showed that AXL1717 can be administered as a single-day BID treatment in very high doses without dose-limiting toxicity. The second part of the trial is ongoing and the patients are now being given AXL1717 daily for 7-28 days BID. Results so far show that AXL1717 can be taken in a multidose setting with good tolerability.

"We are very excited about our new clinical data on AXL1717 and pleased to be able to present them at this important scientific meeting" says Johan Harmenberg, CEO of Axelar AB. "Of particular interest is that even though the clinical trial so far was not designed to demonstrate efficacy, a number of patients show signs of tumor necrosis on PET (positron emission tomography). Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy may become an effective and well-tolerated treatment alternative for cancer patients in the future".

About AXL1717, the IGF-1 Receptor and Cancer

AXL1717 is an orally administered small-molecule IGF-1 receptor inhibitor with no effect on the important and almost identical insulin receptor. Pre-clinical data on AXL1717 have shown an extraordinary anti-tumor efficacy in animal models, including complete regression of a wide range of human cancers.

The IGF-1 receptor is a validated target for anticancer treatment, the recept
'/>"/>

SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
2. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
3. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... 18, 2014 Reports from CDC ... States suffer from one or more chronic health conditions ... Medication can address some of these diseases, but may ... many sufferers face. While implanted nerve stimulation devices today ... whole nerve, which can induce side effects. , ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... Help Drive Production Efficiency and Reliability for New Shire ... HON ) today announced it ... research and development capabilities for creating life-saving medications. Shire ... plc, will use several Honeywell solutions - including ...
... the world renowned Japanese Asahi Breweries announced a new partnership, which ... Japan between Mitsui and Asahi. , ... Lexington, KY ... world renowned Japanese Asahi Breweries announced a new partnership, which will ...
... 11 VERIDIAM ( www.veridiam.com ), a major ... and assemblies, custom engineered to meet the needs ... other highly-critical applications, today announced the appointment of ... Gale will head up operations of all Veridiam ...
Cached Biology Technology:Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 2Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 3Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 4Alltech, Mitsui and Asahi Breweries Create New Venture 2Alltech, Mitsui and Asahi Breweries Create New Venture 3Veridiam Appoints Andrew Gale as Chief Executive Officer 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2009-05/sfeb-cai052609.php,">Chinese . Researchers ... expression of a form of cytochrome P-450 (CYP4B1) ... in mice by caffeic acid, an anti-inflammatory antioxidant ... which appear in the June 2009 issue of ...
... a soldier is wounded during combat, surgeons must focus ... Technologies that could improve the repair and regeneration processes ... but they are not being moved quickly enough into ... Georgia Tech Center for Advanced Bioengineering for Soldier Survivability ...
... by millions worldwide to effectively lower blood cholesterol levels, ... (MS) patients treated with high daily dosages. A ... (MNI), McGill University, demonstrates that statin therapy in mice ... system. The findings, published in The American Journal ...
Cached Biology News:Caffeic acid inhibits colitis in a mouse model -- is a drug-metabolizing gene crucial? 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 3One size does not fit all 2
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Store vial at -20 C prior to opening. ... contents and freeze at -20 C or below. Avoid ... Other Sub-Family: not assigned-Other ...
... powder containing carbohydrate and citrate buffer ... One unit will convert 1.0 mole ... D -glucose 6-phosphate per min ... Chem comp: Protein ~ ...
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
Biology Products: